We describe the procedure to isolate genomic DNA, RNA, and protein directly from cryopreserved induced pluripotent stem cell (iPSC) vials using commercially available solid‐phase extraction kits, and we report the relationship between macromolecule yields and experimental and storage factors. Sufficient quantities of DNA, RNA, and protein are recoverable from as low as 1 million cryopreserved cells across 728 distinct iPSC lines suitable for whole‐genome sequencing, RNA sequencing, and mass spectrometry experiments. Nucleic acids extracted from iPSC stocks cryopreserved up to 4 years maintain sufficient quantity and integrity for downstream analysis with minimal genomic DNA fragmentation. An expected positive correlation exists between cell count and DNA or RNA yield, with comparable yields recovered between cells across different cryostorage timespans. This article provides an effective way to simultaneously isolate iPSC biomolecules for multi‐omics investigations.
J. Lee, V. Termglinchan, S. Diecke, I. Itzhaki, C. K. Lam, P. Garg, E. Lau, M. Greenhaw, T. Seeger, H. Wu, J. Z. Zhang, X. Chen, I. P. Gil, M. Ameen, K. Sallam, J.-W. Rhee, J. M. Churko, R. Chaudhary, T. Chour, P. J. Wang, M. P. Snyder, H. Y. Chang, I. Karakikes, and J. C. WuNature, 572(7769), 335—340, 2019
Human induced pluripotent stem cells (iPSCs) provide a renewable supply of patient-specific and tissue-specific cells for cellular and molecular studies of disease mechanisms. Combined with advances in various omics technologies, iPSC models can be used to profile the expression of genes, transcripts, proteins, and metabolites in relevant tissues. In the past 2 years, large panels of iPSC lines have been derived from hundreds of genetically heterogeneous individuals, further enabling genome-wide mapping to identify coexpression networks and elucidate gene regulatory networks. Here, we review recent developments in omics profiling of various molecular phenotypes and the emergence of human iPSCs as a systems biology model of human diseases.
A. S. Lee, M. Inayathullah, M. A. Lijkwan, X. Zhao, W. Sun, S. Park, W. X. Hong, M. B. Parekh, A. V. Malkovskiy, E. Lau, X. Qin, V. R. Pothineni, V. Sanchez-Freire, W. Y. Zhang, N. G. Kooreman, A. D. Ebert, C. K. F. Chan, P. K. Nguyen, J. Rajadas, and J. C. WuNature biomedical engineering, 2(2), 104—113, 2018
F. Olmeta-Schult, L. M. Segal, S. Tyner, T. A. Moon, R. D.-W. Chow, P. Chakrabarty, M. Pacesa, A. I. Podgornaia, J. Chen, B. Singh, B. Cao, R. R. S. Sidhu, B. W. Q. Tan, P. Sood, S. Parker, M. A. Scult, D. V. Haute, N. Konstantinides, B. A. Schwendimann, S. Srivastava, R. Fiorenza, K. Dutton-Regester, R. Hale, E. O. Polat, E. Lau, A. L. Mayer, and E. R. WhiteScience (New York, N.Y.), 359(6371), 26—28, 2018
Transcript abundance and protein abundance show modest correlation in many biological models, but how this impacts disease signature discovery in omics experiments is rarely explored. Here we report an integrated omics approach, incorporating measurements of transcript abundance, protein abundance, and protein turnover to map the landscape of proteome remodeling in a mouse model of pathological cardiac hypertrophy. Analyzing the hypertrophy signatures that are reproducibly discovered from each omics data type across six genetic strains of mice, we find that the integration of transcript abundance, protein abundance, and protein turnover data leads to 75% gain in discovered disease gene candidates. Moreover, the inclusion of protein turnover measurements allows discovery of post-transcriptional regulations across diverse pathways, and implicates distinct disease proteins not found in steady-state transcript and protein abundance data. Our results suggest that multi-omics investigations of proteome dynamics provide important insights into disease pathogenesis in vivo.
Mitochondrial proteins carry out diverse cellular functions including ATP synthesis, ion homeostasis, cell death signaling, and fatty acid metabolism and biogenesis. Compromised mitochondrial quality control is implicated in various human disorders including cardiac diseases. Recently it has emerged that mitochondrial protein turnover can serve as an informative cellular parameter to characterize mitochondrial quality and uncover disease mechanisms. The turnover rate of a mitochondrial protein reflects its homeostasis and dynamics under the quality control systems acting on mitochondria at a particular cell state. This review article summarizes some recent advances and outstanding challenges for measuring the turnover rates of mitochondrial proteins in health and disease. This article is part of a Special Issue entitled "Mitochondria: From Basic Mitochondrial Biology to Cardiovascular Disease".